- Active, not recruiting
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
Updated: Sep 7, 2022
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Elo-KRd
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 55 subjects will be enrolled. Time to progression or death will be calculated from the date of first treatment on protocol until the date of disease progression or death from any cause. Patients can expect to participate between 12-24 cycles. The primary endpoint will be the rate of response by next generation gene sequencing at the end of 8 cycles among non-transplant candidates and transplant candidates who agreed to defer transplant.
Sponsor:
University of Chicago
Collaborators:
Bristol-Myers Squibb
Amgen
Multiple Myeloma Research Foundation
ClinicalTrials.gov Identifier: NCT02969837
Official Title: Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
First Posted: November 21, 2016
Click here for details on ClinicalTrials.gov
Elotuzumab : National Cancer Institute
Elotuzumab : MedlinePlus Drug Information
Lenalidomide: National Cancer Institute
Lenalidomide: MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Carfilzomib : National Cancer Institute
Carfilzomib : MedlinePlus Drug Information
Drug: Elotuzumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Adaptive Biotechnologies
Multiple Myeloma Research Consortium
Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM)
Journal of Clinical Oncology;2021 ASCO Annual Meeting
Click here for details
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study
JAMA Oncol;2022 Ju
Click here for details
Location
United States, Illinois
United States, Michigan